Evidence map›Paper›PMID 31336942›Full record

ArticleCells2019

Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer.

Hagen Kulbe, Raik Otto, Silvia Darb-Esfahani, Hedwig Lammert, Salem Abobaker, Gabriele Welsch, Radoslav Chekerov, Reinhold Schäfer, Duska Dragun, Michael Hummel and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hagen KulbeTumourbank Ovarian Cancer Network, 13353 Berlin, Germany.ORCID 0000-0002-4367-289X
Raik OttoInstitute for Computer Sciences, Humboldt-Universität zu Berlin, 12489 Berlin, Germany.ORCID 0000-0003-3644-743X
Silvia Darb-EsfahaniTumourbank Ovarian Cancer Network, 13353 Berlin, Germany.
Hedwig LammertInsititute for Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
Salem AbobakerTumourbank Ovarian Cancer Network, 13353 Berlin, Germany.
Gabriele WelschTumourbank Ovarian Cancer Network, 13353 Berlin, Germany.
Radoslav ChekerovTumourbank Ovarian Cancer Network, 13353 Berlin, Germany.
Reinhold SchäferInsititute for Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.ORCID 0000-0001-7952-2124
Duska DragunDepartment of Nephrology and Transplantation, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany.
Michael HummelInsititute for Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
Ulf LeserInstitute for Computer Sciences, Humboldt-Universität zu Berlin, 12489 Berlin, Germany.
Jalid SehouliTumourbank Ovarian Cancer Network, 13353 Berlin, Germany.
Elena Ioana BraicuTumourbank Ovarian Cancer Network, 13353 Berlin, Germany. elena.braicu@charite.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Detection of epithelial ovarian cancer (EOC) poses a critical medical challenge. However, novel biomarkers for diagnosis remain to be discovered. Therefore, innovative approaches are of the utmost importance for patient outcome. Here, we present a concept for blood-based biomarker discovery, investigating both epithelial and specifically stromal compartments, which have been neglected in search for novel candidates. We queried gene expression profiles of EOC including microdissected epithelium and adjacent stroma from benign and malignant tumours. Genes significantly differentially expressed within either the epithelial or the stromal compartments were retrieved. The expression of genes whose products are secreted yet absent in the blood of healthy donors were validated in tissue and blood from patients with pelvic mass by NanoString analysis. Results were confirmed by the comprehensive gene expression database, CSIOVDB (Ovarian cancer database of Cancer Science Institute Singapore). The top 25% of candidate genes were explored for their biomarker potential, and twelve were able to discriminate between benign and malignant tumours on transcript levels (

Indexed as

Carcinoma, Ovarian EpithelialOvarian NeoplasmsAdultAgedAged, 80 and overAurora Kinase ABiomarkers, TumorDatasets as TopicFemaleHumansMiddle AgedMyelin and Lymphocyte-Associated Proteolipid ProteinsSyndecan-3TranscriptomeVersicansYoung AdultAURKA protein, humanAurora Kinase ABiomarkers, TumorMAL protein, humanMyelin and Lymphocyte-Associated Proteolipid ProteinsSDC3 protein, humanSyndecan-3VCAN protein, humanVersicansbiomarker discoverydifferential expressionovarian cancertumour microenvironment

Identifiers

PMID31336942
PMCPMC6678810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.